Navigation Links
MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
Date:6/16/2009

Phase 3 PROTEGE ENCORE Clinical Trial Initiated

ROCKVILLE, Md. and INDIANAPOLIS, June 16 /PRNewswire/ -- MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the PROTEGE trial achieved its targeted patient enrollment. The trial is a pivotal Phase 2/3 clinical study evaluating teplizumab, an investigational compound under development for the treatment of individuals with recent-onset type 1 diabetes.

The PROTEGE trial is a randomized, double-blind, multi-center, multi-national, 4-arm, controlled study designed to evaluate the safety and efficacy of teplizumab in individuals with recent-onset type 1 diabetes, aged 8 to 35, who are within 12 weeks of their diagnosis. More than 530 individuals are enrolled in the study across 14 countries, including the United States. The primary composite endpoint for PROTEGE includes both the patient's total daily insulin usage and his/her HbA1c levels at 12 months. Secondary endpoints are evaluated at 24 months. Longer term safety and efficacy data from patients who complete the PROTEGE trial are being collected in a separate Phase 3 study called the PROTEGE Extension trial.

"The completion of enrollment of the PROTEGE study is an important milestone for MacroGenics and for the type 1 diabetes research community," stated Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "We appreciate the dedication of the patients, their caregivers and clinical investigators who helped advance this important late-stage clinical trial."

The companies also announced today that they have initiated the PROTEGE ENCORE trial, another Phase 3 global study of teplizumab in individuals with recent-onset type 1 diabetes, designed to capture patient-reported outcome measures in addition to safety and efficacy data. Information about the PROTEGE and PROTE
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
3. Study Showed Lillys GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients
4. Lilly Advances Second Alzheimers Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials
5. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
6. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
7. FDA Issues a Complete Response Letter for Lillys Olanzapine LAI for Treatment of Schizophrenia in Adults
8. Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
9. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
10. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
11. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 STAAR Surgical Company (NASDAQ: ... marketer of minimally invasive ophthalmic products, today announced that ... review the Company,s recent financial results and business developments ... will present at the 38 th Annual Deutsche ... at the Westin Waterfront Hotel on Wednesday, May ...
(Date:5/20/2013)... --   , Campaign launched ... to address the large physical and economic costs of ... affect 700 million people annually and account for 30 ... ,Do You Mind?, helps patients, family members, policymakers and ... collectively address MNDs , Today the International ...
(Date:5/20/2013)... Landauer, Inc. (NYSE: LDR ), ... and monitoring, outsourced medical physics services and high quality ... Directors declared, at its meeting on May 16, 2013, ... for the third quarter of fiscal 2013.  The dividend ... of record on June 7, 2013. About ...
Breaking Medicine Technology:STAAR Surgical To Present At Upcoming Investor Conferences 2Research-based Pharmaceutical Industry Launches 'Do You Mind?' Campaign to Fight Mental and Neurological Disorders 2Landauer, Inc. Declares Regular Cash Dividend 2
... TULSA, Okla., Sept. 1, 2011 Hillcrest ... SouthCrest Hospital in Tulsa, Okla., and Claremore Regional Hospital ... the agreement were not disclosed. The transaction ... Hospital, the 89-bed Claremore Regional Hospital, more than 70 ...
... PAUL, Minn., Sept. 1, 2011 Angeion Corporation (NASDAQ: ... third quarter ended July 31, 2011. Angeion ... the third quarter of fiscal 2010. Angeion incurred a net ... income of $126,000, or $0.03 per diluted share in the ...
Cached Medicine Technology:Hillcrest Completes Purchase of SouthCrest & Claremore Hospitals 2Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 2Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 3Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 4Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 5Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 6Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results 7
(Date:5/21/2013)... of sudden infant death syndrome (SIDS) is five times ... study finds. British researchers noted that bed-sharing increases ... drink, use illegal drugs or smoke. They advised that ... infant death in developed countries, would drop dramatically if ... the United States, all parents are advised to not ...
(Date:5/21/2013)... The warning images Brussels proposes to include on tobacco ... the desired impact on smokers because they only find ... Commission wants to improve the efficacy of its anti-smoking ... that make a stronger emotional impact., These are some ... of Personality, Evaluation and Psychological Treatment at the University ...
(Date:5/21/2013)... known for their health benefits, and the subtropical ... drugs are delivered to specific tumor cells. , ... create nanoparticles using natural lipids derived from grapefruit, ... drug delivery vehicles. UofL scientists Huang-Ge Zhang, D.V.M., ... (May 21, 2013), published their findings in ...
(Date:5/21/2013)... Representatives with Hammerhead Bicycles announced today that their re-launched bike ... achieved its overall goal of becoming a standalone brand. , ... Bicycles from a house brand to a standalone bike brand,” ... that the bike shop will go forward as Switchback ... 29er and 650b. , “The bike shop will ...
(Date:5/21/2013)... 21, 2013 TheBeautyPlace.com helps brides to ... features a Big Day Kit including all the essentials ... to shine on their Wedding Day. , TheBeautyPlace.com features ... about on their Wedding Day. Flowers blooming and warmer ... of wedding season. From Memorial Day to October, brides ...
Breaking Medicine News(10 mins):Health News:Bed-Sharing Raises SIDS Risk Fivefold, Study Finds 2Health News:Warning images for cigarette packs proposed by Europe do not make enough emotional impact 2Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Hammerhead Bicycles Now a Standalone Brand 2Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 2Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 3
... Itamar Medical ... ... Medicine, Mayo Clinic, Rochester, MN Dr. Peter Friberg, Sahlgrenska University ... Mr. Israel Schreiber, President and CEO, Itamar Medical ...
... reduced heart risks after angioplasty/stenting, but raised bleeding risks ... -- A new anti-clotting drug might one day challenge Plavix, ... procedures to open blocked coronary arteries, a new study suggests. ... -- notably those who had had a prior stroke, were ...
... ORLANDO, FL A North Carolina team of doctors, ... up with a way to provide faster, more effective ... require expensive drugs or fancy new equipment. But it ... on everyone involved to move treatment forward empowering ...
... Calif., Nov. 4 Consistent implementation of,proven ... to a Kaiser,Permanente (KP) abstract, published this ... in Orlando, Florida. The researchers followed ... to Kaiser Permanente emergency departments in Northern,California ...
... research suggests , , SUNDAY, Nov. 4 (HealthDay News) ... typically need open-heart surgery might someday have a new, ... , The balloon is inserted percutaneously (through the skin), ... said. In a new study, the procedure -- not ...
... risk of major cardiovascular events by 19, percent, significantly ... ... bleeding, TOKYO and INDIANAPOLIS, Nov. 4 ... investigational,antiplatelet agent prasugrel produced a highly significant 19 percent,reduction in relative ...
Cached Medicine News:Health News:How Early Can We Detect Cardiovascular Disease Less Expensively ... Even in Childhood? 2Health News:New Anti-Clotting Drug Shows Promise in Heart Patients 2Health News:New Anti-Clotting Drug Shows Promise in Heart Patients 3Health News:RACE: a statewide model of better, faster heart attack care 2Health News:RACE: a statewide model of better, faster heart attack care 3Health News:Following Heart Disease Guidelines Saves Lives, According to a Kaiser Permanente Abstract Presented at AHA Scientific Sessions 2Health News:Following Heart Disease Guidelines Saves Lives, According to a Kaiser Permanente Abstract Presented at AHA Scientific Sessions 3Health News:Balloon Valve May Be Alternative to Open-Heart Surgery 2Health News:Balloon Valve May Be Alternative to Open-Heart Surgery 3Health News:In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack 2Health News:In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack 3Health News:In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack 4Health News:In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack 5Health News:In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack 6Health News:In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack 7
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
50L...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
... Reference Series 2000 Pipette is a synonym ... compact and robust design, and superior operating ... to operate the measuring stroke and blow-out ... features:Eppendorf "pipette/tip" system ensures utmost accuracy and ...
Medicine Products: